1. reported pregnancy or breastfeeding

1. reported pregnancy or breastfeeding

reported pregnancy or breastfeeding history of severe neurological conditions, e.g. transverse myelitis, guillain-barre syndrome (gbs), demyelinating diseases

reported pregnancy or breastfeeding history of severe neurological conditions, e.g. transverse myelitis, guillain-barre syndrome (gbs), demyelinating diseases

1. reported pregnancy or breastfeeding 2. history of severe neurological conditions, e.g. transverse myelitis, guillain-barre syndrome (gbs), demyelinating diseases

1. reported pregnancy or breastfeeding 2. history of severe neurological conditions, e.g. transverse myelitis, guillain-barre syndrome (gbs), demyelinating diseases

8. known history of covid-19 9. history of severe allergy, such as angioedema, bronchospasm and/or hypotension to food, drug, vaccine, or unknown trigger 10. history of steven-johnson syndrome (sjs), toxic epidermal necrolysis (ten), drug rash with eosinophilia and systemic syndrome (dress)/drug-induced hypersensitivity syndrome (dihs) 11. any significant medical or psychiatric condition including laboratory abnormalities or suicidal ideation and behaviour within past 12 months that may increase risk of vaccination 12. severe immunocompromise, including present or planned use of cytotoxic agents or systemic immunosuppressives, known primary or secondary immunodeficiency diseases. short-term systemic steroids use (<14 days) for an acute condition precludes the participant from receiving study vaccines until 28 days after the termination of said therapy 13. receipt of blood or plasma products or immunoglobulin within 60 days prior to vaccination to conclusion of the study 14. any haematological diseases (that preclude intramuscular injection) 15. reported pregnancy or breastfeeding 16. receipt of coronavirus vaccines in the past 17. history of severe neurological conditions, e.g. transverse myelitis, guillain-barre syndrome (gbs), demyelinating diseases

8. known history of covid-19 9. history of severe allergy, such as angioedema, bronchospasm and/or hypotension to food, drug, vaccine, or unknown trigger 10. history of steven-johnson syndrome (sjs), toxic epidermal necrolysis (ten), drug rash with eosinophilia and systemic syndrome (dress)/drug-induced hypersensitivity syndrome (dihs) 11. any significant medical or psychiatric condition including laboratory abnormalities or suicidal ideation and behaviour within past 12 months that may increase risk of vaccination 12. severe immunocompromise, including present or planned use of cytotoxic agents or systemic immunosuppressives, known primary or secondary immunodeficiency diseases. short-term systemic steroids use (<14 days) for an acute condition precludes the participant from receiving study vaccines until 28 days after the termination of said therapy 13. receipt of blood or plasma products or immunoglobulin within 60 days prior to vaccination to conclusion of the study 14. any haematological diseases (that preclude intramuscular injection) 15. reported pregnancy or breastfeeding 16. receipt of coronavirus vaccines in the past 17. history of severe neurological conditions, e.g. transverse myelitis, guillain-barre syndrome (gbs), demyelinating diseases

8. known history of covid-19 9. history of severe allergy, such as angioedema, bronchospasm and/or hypotension to food, drug, vaccine, or unknown trigger 10. history of steven-johnson syndrome (sjs), toxic epidermal necrolysis (ten), drug rash with eosinophilia and systemic syndrome (dress)/drug-induced hypersensitivity syndrome (dihs) 11. any significant medical or psychiatric condition including laboratory abnormalities or suicidal ideation and behaviour within past 12 months that may increase risk of vaccination 12. severe immunocompromise, including present or planned use of cytotoxic agents or systemic immunosuppressives, known primary or secondary immunodeficiency diseases. short-term systemic steroids use (<14 days) for an acute condition precludes the participant from receiving study vaccines until 28 days after the termination of said therapy 13. receipt of blood or plasma products or immunoglobulin within 60 days prior to vaccination to conclusion of the study 14. any haematological diseases (that preclude intramuscular injection) 15. reported pregnancy

8. known history of covid-19 9. history of severe allergy, such as angioedema, bronchospasm and/or hypotension to food, drug, vaccine, or unknown trigger 10. history of steven-johnson syndrome (sjs), toxic epidermal necrolysis (ten), drug rash with eosinophilia and systemic syndrome (dress)/drug-induced hypersensitivity syndrome (dihs) 11. any significant medical or psychiatric condition including laboratory abnormalities or suicidal ideation and behaviour within past 12 months that may increase risk of vaccination 12. severe immunocompromise, including present or planned use of cytotoxic agents or systemic immunosuppressives, known primary or secondary immunodeficiency diseases. short-term systemic steroids use (<14 days) for an acute condition precludes the participant from receiving study vaccines until 28 days after the termination of said therapy 13. receipt of blood or plasma products or immunoglobulin within 60 days prior to vaccination to conclusion of the study 14. any haematological diseases (that preclude intramuscular injection) 15. reported pregnancy